Fulltext

Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer

Saw SPL 1 , Zhong WZ 2 , Fu R 2 , Li MSC 3 , Goto Y 4 , Fox SB 5 Show all authors , Yatabe Y 6 , Ong BH 7 , Ng CSH 8 , Lee DDW 9 , Cam Phuong P 10 , Park IK 11 , Yang JCH 12 , Tsuboi M 13 , Tho LM 14 , John T 15 , Hsu HH 16 , Tan DSW 17 , Mok TSK 3 , Reungwetwattana T 18 , Singh N 19

Affiliations 

  • 1 Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore. Electronic address: stephanie.saw.p.l@singhealth.com.sg
  • 2 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
  • 3 Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong China
  • 4 National Cancer Center Hospital, Department of Thoracic Oncology, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
  • 5 Department of Pathology, Peter MacCallum Cancer Centre and University of Melbourne, Australia
  • 6 Department of Diagnostic Pathology, National Cancer Center, Tokyo, Japan
  • 7 Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore
  • 8 Department of Surgery, The Chinese University of Hong Kong, Hong Kong Special Administrative Region
  • 9 Department of Clinical Oncology, University of Malaya, Kuala Lumpur, Malaysia
  • 10 The Nuclear Medicine and Oncology Center, Bach Mai Hospital, 78 Giai Phong Street, Dong Da, Hanoi, Viet Nam
  • 11 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea
  • 12 Department of Oncology, National Taiwan University Hospital, Taiwan
  • 13 Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 14 Department of Oncology, Beacon Hospital, Petaling Jaya, Malaysia
  • 15 Medical Oncologist, Peter MacCallum Cancer Centre and University of Melbourne, Australia
  • 16 Department of Surgical Oncology and Surgery, National Taiwan University Cancer Center and College of Medicine, National Taiwan University, Taipei, Taiwan
  • 17 Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore
  • 18 Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 19 Lung Cancer Clinic, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
Lung Cancer, 2025 Feb;200:108076.
PMID: 39799810 DOI: 10.1016/j.lungcan.2024.108076

Abstract

The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions. An interdisciplinary group of 19 experts comprising medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists and pathologists from Singapore, Hong Kong, Mainland China, Korea, Japan, Taiwan, India, Malaysia, Thailand, Vietnam and Australia met to discuss emerging data, identify existing gaps in clinical care and develop a multidisciplinary, multinational expert consensus statement on the peri-operative management of NSCLC tailored to the Asia-Pacific region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications